TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3395307

Group type: EXPERIMENTAL
Intervention: Feingold diet (6 weeks)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Synthetic food colourings (50 mg of tartrazine or carmoisine for 2 weeks each)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo (during lead-in and washout periods)
Number of subjects: 55
Study: 31339245

Group type: EXPERIMENTAL
Intervention: Long-acting injectable antipsychotics (LAI AP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral antipsychotics
Number of subjects: 0
Study: 28803535

Group type: EXPERIMENTAL
Intervention: High robotic assistance (82% success at hitting targets)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low robotic assistance (55% success at hitting targets)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High robotic assistance
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low robotic assistance
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both high and low robotic assistance
Number of subjects: 30
Study: 24566799

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 23892047

Group type: EXPERIMENTAL
Intervention: C3a priming of UCB unit
Number of subjects: 30

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 30
Study: 21478739

Group type: EXPERIMENTAL
Intervention: Novel user interface
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard electronic medical record
Number of subjects: 20
Study: 19170461

Group type: EXPERIMENTAL
Intervention: Therapist-aided exposure (maximum of three 2-hr sessions during 1 week)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Therapist-aided exposure
Number of subjects: 10
Study: 16498159

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 259
Study: 12724018

Group type: EXPERIMENTAL
Intervention: Genistein (group A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Calcium (group B)
Number of subjects: 70
Study: 10392347

Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Porcine insulin
Number of subjects: 17
Study: 11951458

Group type: EXPERIMENTAL
Intervention: Monitoring cerebral blood flow, arteriovenous difference of oxygen, saturation of jugular venous blood flow with oxygen, and cerebral metabolic rate of oxygen
Number of subjects: 0
Study: 1859004

Group type: EXPERIMENTAL
Intervention: Intravenous alfentanil
Number of subjects: 24

Group type: COMPARATOR
Intervention: Epidural alfentanil
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (iv and epidural)
Number of subjects: 24
Study: 6345478

Group type: EXPERIMENTAL
Intervention: Guar gum granules, 15 g/d for 3 months
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Guar gum granules
Number of subjects: 12
Study: 31144308

Group type: EXPERIMENTAL
Intervention: Caring for Children Through Conflict and Displacement intervention
Number of subjects: 120
Study: 31323048

Group type: EXPERIMENTAL
Intervention: Pharmacist consultation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 35
Study: 28551083

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study: 26150193

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent
Number of subjects: 680

Group type: COMPARATOR
Intervention: First-generation drug-eluting stent
Number of subjects: 680
Study: 23341895

Group type: EXPERIMENTAL
Intervention: Pictorial warning labels
Number of subjects: 3371

Group type: COMPARATOR
Intervention: Text-only warning labels
Number of subjects: 3371
Study: 21928127

Group type: EXPERIMENTAL
Intervention: 100 mg MgSO(4) plus 15 mg bupivacaine 0.5%
Number of subjects: 79

Group type: COMPARATOR
Intervention: 15 mg bupivacaine 0.5% with 0.2 ml normal saline (control group)
Number of subjects: 79
Study: 18256870

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 22

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 22
Study: 17024872

Group type: EXPERIMENTAL
Intervention: Tandem autologous transplants followed by maintenance therapy
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Sequential autologous transplants followed by nonmyeloablative allotransplants
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Induction and/or consolidation treatments
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Risk-adapted transplant approaches
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Conventional myeloablative allogeneic transplants
Number of subjects: 5000
Study: 15022177

Group type: EXPERIMENTAL
Intervention: Harpagophytum extracts with 50-60 mg harpagoside daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Proprietary ethanol extract with lower harpagoside dosage
Number of subjects: 0
Study: 10893344

Group type: EXPERIMENTAL
Intervention: 1 mU x kg(‐1) x min(‐1) insulin infusion for 180 min
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 5 mU x kg(‐1) x min(‐1) insulin infusion for 180 min
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fasting conditions
Number of subjects: 18
Study: 8846752

Group type: EXPERIMENTAL
Intervention: Patients with Parkinson's disease (PD)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 46
Study: 1352567

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (325 mg on alternate days)
Number of subjects: 22071

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22071
Study: 6090014

Group type: EXPERIMENTAL
Intervention: Doxorubicin (40 mg/m2 iv every 3 weeks) and Mitomycin (12 mg/m2 iv every 6 weeks)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Cisplatin (80 mg/m2 iv every 3 weeks X 3, then every 6 weeks) and Etoposide (80 mg/m2 iv on Days 1‐3 every 3 weeks X 3, then every 6 weeks)
Number of subjects: 77
Study: 3538450

Group type: EXPERIMENTAL
Intervention: Sulindac (Clinoril; Frosst‐MSD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 30
Study: 29368658

Group type: EXPERIMENTAL
Intervention: Laparoscopic supracervical hysterectomy (LASH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Second generation endometrial ablation (EA)
Number of subjects: 0
Study: 27914499

Group type: EXPERIMENTAL
Intervention: 8 weeks of supervised combined endurance and resistance exercise
Number of subjects: 30

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 30
Study: 24166510

Group type: COMPARATOR
Intervention: Control drink (CR)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Human Ration drink (CRHR)
Number of subjects: 22
Study: 22410021

Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg per hr after an induction bolus of 2 mg/kg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (midazolam 0.2 mg/kg for induction without intravenous anesthetic infusion for maintenance)
Number of subjects: 19
Study: 20709767

Group type: EXPERIMENTAL
Intervention: Google
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UpToDate
Number of subjects: 0

Group type: COMPARATOR
Intervention: PubMed
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ovid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Google and UpToDate
Number of subjects: 0
Study: 18215542

Group type: EXPERIMENTAL
Intervention: Eating and drinking while driving
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal driving
Number of subjects: 0
Study: 15993354

Group type: EXPERIMENTAL
Intervention: Intensive glycemic treatment
Number of subjects: 153

Group type: COMPARATOR
Intervention: Standard glycemic treatment
Number of subjects: 153
Study: 12544527

Group type: EXPERIMENTAL
Intervention: LigaSure vessel sealing system
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional Ferguson procedure
Number of subjects: 61
Study: 10655925

Group type: EXPERIMENTAL
Intervention: Laryngeal mask size 5 (males)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Laryngeal mask size 4 (females)
Number of subjects: 63
Study: 8918002

Group type: EXPERIMENTAL
Intervention: Tempe-yellow maize porridge (TYMP)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Milk-yellow maize porridge (MYMP)
Number of subjects: 117
Study: 1887741

Group type: EXPERIMENTAL
Intervention: Suggestion group (N = 38)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (N = 42)
Number of subjects: 80
Study: 6348485

Group type: EXPERIMENTAL
Intervention: Opipramol (50 mg sugar-coated tablets)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Opipramol
Number of subjects: 48
Study: 31538305

Group type: EXPERIMENTAL
Intervention: Macuprev Supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 29487223

Group type: EXPERIMENTAL
Intervention: Metformin plus carboplatin, paclitaxel, and bevacizumab (Arm A)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Carboplatin, paclitaxel, and bevacizumab without metformin (Arm B)
Number of subjects: 25
Study: 26655368

Group type: EXPERIMENTAL
Intervention: Wheelchair‐bound Senior Elastic Band (WSEB) group‐exercises, conducted three times per week for 40 minutes per session, first six months volunteer-led, followed by six months DVD-guided.
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Wheelchair‐bound Senior Elastic Band (WSEB) group‐exercises.
Number of subjects: 127
Study: 25041441

Group type: EXPERIMENTAL
Intervention: Subgingival air-polishing with erythritol powder containing 0.3% chlorhexidine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ultrasonic debridement
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Subgingival air-polishing
Number of subjects: 50
Study: 21805085

Group type: EXPERIMENTAL
Intervention: Daflon (micronised purified flavonoid fraction)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 20723640

Group type: EXPERIMENTAL
Intervention: Interleukin-6
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Aldosterone
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Matrix metalloproteinase-9
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Biomarker strategy including interleukin-6, B-type natriuretic peptide, aldosterone, and matrix metalloproteinase-9
Number of subjects: 440
Study: 17650271

Group type: EXPERIMENTAL
Intervention: Assertive community treatment
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard community mental health care
Number of subjects: 118
Study: 16537213

Group type: EXPERIMENTAL
Intervention: Combination device involving radiofrequency, infrared light, and mechanical suction-based massage (20 watts RF, 20 watts IR, 200 millibar vacuum)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-treated control (contralateral thigh)
Number of subjects: 20
Study: 11727130

Group type: EXPERIMENTAL
Intervention: Transabdominal preperitoneal (TAPP) hernia repair
Number of subjects: 100

Group type: COMPARATOR
Intervention: Shouldice hernia repair
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: TAPP hernia repair
Number of subjects: 100
Study: 9132344

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LAE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open appendectomy (OAE)
Number of subjects: 0
Study: 7945629

Group type: EXPERIMENTAL
Intervention: 2 mg intracervical PgE2 gel
Number of subjects: 960
Study: 2908030

Group type: EXPERIMENTAL
Intervention: CV 205-502 (0.05 to 0.15 mg once daily for 6 months)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CV 205-502
Number of subjects: 24
Study: 31828755

Group type: EXPERIMENTAL
Intervention: Flow-controlled ventilation (FCV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Baseline ventilation (BL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Volume-controlled ventilation (VCV)
Number of subjects: 20
Study: 31479717

Group type: EXPERIMENTAL
Intervention: WW + Tyr (white wine plus 25 mg Tyr capsule)
Number of subjects: 33
Study: 28614675

Group type: EXPERIMENTAL
Intervention: Hospital Value-Based Purchasing (HVBP) program
Number of subjects: 1364
Study: 25580916

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) plus risperidone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Risperidone plus placebo
Number of subjects: 40
Study: 23425772

Group type: EXPERIMENTAL
Intervention: ω-3 fatty acids (1440 mg/day, n=8)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (n=10)
Number of subjects: 18
Study: 21035980

Group type: EXPERIMENTAL
Intervention: 10 mg loading dose of warfarin
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5 mg dose of warfarin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enoxaparin (1.5 mg/kg per day)
Number of subjects: 0
Study: 19380898

Group type: EXPERIMENTAL
Intervention: Ezetimibe
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ezetimibe/Simvastatin
Number of subjects: 41

Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 41
Study: 16769916

Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering therapy
Number of subjects: 210

Group type: COMPARATOR
Intervention: Moderate lipid-lowering therapy
Number of subjects: 210
Study: 15207210

Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 32

Group type: COMPARATOR
Intervention: No pilocarpine (Control)
Number of subjects: 32
Study: 11223900

Group type: EXPERIMENTAL
Intervention: Culturally sensitive AIDS education video intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9141579

Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Number of subjects: 150

Group type: COMPARATOR
Intervention: Cardiotocography
Number of subjects: 150
Study: 7835816

Group type: EXPERIMENTAL
Intervention: Cisplatin plus cyclophosphamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carboplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taxol plus cisplatin
Number of subjects: 0
Study: 3296159

Group type: EXPERIMENTAL
Intervention: Low-dose heparin (5000 I.U. subcutaneous injection once a day for 5 consecutive weekdays)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (subcutaneous injection once a day for 5 consecutive weekdays)
Number of subjects: 20
Study: 31982480

Group type: EXPERIMENTAL
Intervention: Exenatide (Bydureon), 12 weeks treatment
Number of subjects: 24
Study: 29887321

Group type: EXPERIMENTAL
Intervention: New vaccines added to the early childhood vaccine schedule (4 new antigens); assessed from 2006 to 2016.
Number of subjects: 3515

Group type: EXPERIMENTAL
Intervention: All vaccines included in the schedule; assessed in 2016.
Number of subjects: 3515

Group type: EXPERIMENTAL
Intervention: New vaccines introduced; assessed within 2 years of their introduction.
Number of subjects: 3515

Group type: EXPERIMENTAL
Intervention: Incomplete vaccine status by 24 months of age; associated factors.
Number of subjects: 3515
Study: 26541692

Group type: EXPERIMENTAL
Intervention: Functional remediation
Number of subjects: 3

Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 3

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 3
Study: 26573910

Group type: EXPERIMENTAL
Intervention: Rapid diagnostic tests (RDTs) for malaria introduced in registered drug shops
Number of subjects: 0
Study: 23153175

Group type: EXPERIMENTAL
Intervention: InnoScope
Number of subjects: 25

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 25
Study: 22047971

Group type: EXPERIMENTAL
Intervention: 600 mg ocrelizumab
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: 2000 mg ocrelizumab
Number of subjects: 220

Group type: COMPARATOR
Intervention: Interferon beta-1a
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 19168445

Group type: EXPERIMENTAL
Intervention: Goserelin (gonadotrophin-releasing hormone analog) for 24 weeks
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Bicalutamide (androgen receptor blocker) for 24 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Untreated men (control group)
Number of subjects: 43
Study: 16842666

Group type: EXPERIMENTAL
Intervention: enalapril + spironolactone (20 mg/d)
Number of subjects: 130

Group type: COMPARATOR
Intervention: enalapril
Number of subjects: 130

Group type: COMPARATOR
Intervention: anti‐hypertensive drugs not directly affecting RAAS (group C)
Number of subjects: 130
Study: 15354041

Group type: EXPERIMENTAL
Intervention: Weight Training Group (WTG)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combined Training Group (CTG)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 22
Study: 11299036

Group type: EXPERIMENTAL
Intervention: Effervescent tablets of chloroquine phosphate 300 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Uncoated tablets of chloroquine phosphate 300 mg
Number of subjects: 60
Study: 7614213

Group type: EXPERIMENTAL
Intervention: ENDEX apex locator
Number of subjects: 61

Group type: COMPARATOR
Intervention: RCM Mark II apex locator
Number of subjects: 61
Study: 2758732

Group type: EXPERIMENTAL
Intervention: Intravenous nalbuphine (0.2 mg/kg) in children (group I)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intravenous nalbuphine (10 mg) in healthy volunteers (group II)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral nalbuphine (30 mg) in healthy volunteers (group II)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intravenous nalbuphine (10 mg) in elderly patients (group III)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral nalbuphine (30 mg) in elderly patients (group III)
Number of subjects: 32
Study: 931391

Group type: EXPERIMENTAL
Intervention: Griseofulvin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Miconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clotrimazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiabendazole
Number of subjects: 0
Study: 30151798

Group type: EXPERIMENTAL
Intervention: IRE-NK group (n=18)
Number of subjects: 40

Group type: COMPARATOR
Intervention: IRE group (n=22)
Number of subjects: 40
Study: 29082904

Group type: EXPERIMENTAL
Intervention: Propofol-suxamethonium
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 66
Study: 26132725

Group type: EXPERIMENTAL
Intervention: Positive framing condition (support)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative framing condition (oppose)
Number of subjects: 0
Study: 24310818

Group type: EXPERIMENTAL
Intervention: Sexually aggressive men
Number of subjects: 78

Group type: COMPARATOR
Intervention: Non-aggressive men
Number of subjects: 78
Study: 22579429

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 4

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 4
Study: 19185975

Group type: EXPERIMENTAL
Intervention: Bipolar TURP
Number of subjects: 70

Group type: COMPARATOR
Intervention: Monopolar TURP
Number of subjects: 70
Study: 17565162

Group type: EXPERIMENTAL
Intervention: Speed of processing training program
Number of subjects: 0
Study: 15766303

Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg/day
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg/day
Number of subjects: 138
Study: 12475661

Group type: EXPERIMENTAL
Intervention: Electromyography‐assisted biofeedback training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pelvic floor muscle training (PFMT) alone
Number of subjects: 30
Study: 9535664

Group type: EXPERIMENTAL
Intervention: Breakfast cereal fortified with 127 microg of folic acid daily
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Breakfast cereal fortified with 499 microg of folic acid daily
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Breakfast cereal fortified with 665 microg of folic acid daily
Number of subjects: 75
Study: 9180980

Group type: EXPERIMENTAL
Intervention: TOF at 0.05 Hz
Number of subjects: 40

Group type: COMPARATOR
Intervention: TOF at 0.08 Hz
Number of subjects: 40
Study: 1918422

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Triiodothyronine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 16
Study: 6122848

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 orally
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Oxytocin intravenously
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Demoxytocin buccally
Number of subjects: 739

Group type: COMPARATOR
Intervention: No oxytocics (after primary amniotomy)
Number of subjects: 739
Study: 30862635

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol with additional use of electrical impedance tomography (EIT)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Inhaled salbutamol without additional use of electrical impedance tomography (EIT)
Number of subjects: 2
Study: 28536463

Group type: EXPERIMENTAL
Intervention: Green tea containing 200mg EGCG
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Isolated EGCG
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (NMD)
Number of subjects: 50
Study: 27611433

Group type: EXPERIMENTAL
Intervention: Respiratory Physical Therapy (RPT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (healthy children)
Number of subjects: 27
Study: 24885136

Group type: EXPERIMENTAL
Intervention: Autologous bone block grafts (AUBB)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Allogeneic bone block grafts (ABB)
Number of subjects: 31
Study: 21777974

Group type: COMPARATOR
Intervention: 14-day standard therapy (lansoprazole, amoxicillin, clarithromycin)
Number of subjects: 1463

Group type: EXPERIMENTAL
Intervention: 5-day concomitant therapy (lansoprazole, amoxicillin, clarithromycin, metronidazole)
Number of subjects: 1463

Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy (5 days of lansoprazole and amoxicillin followed by 5 days of lansoprazole, clarithromycin, and metronidazole)
Number of subjects: 1463
Study: 19565743

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Positive control methods
Number of subjects: 0
Study: 17565935

Group type: EXPERIMENTAL
Intervention: verum 1 (nondenaturated isolated soy protein)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: verum 2 (conventional isolated soy protein)
Number of subjects: 120

Group type: COMPARATOR
Intervention: placebo (milk protein)
Number of subjects: 120